Reduced methyltransferase-like 3 and 14 expression and concomitant diminished m6A modification has been reported in many neurodegenerative diseases including Alzheimer’s disease and ALS/FTD which could explain reduced LMTK2 expression in these disorders although further work is needed to confirm this possibility [131–133]. Here, LMTK2 is linked to neurodegenerative disease.